{'fraction_non_alphanumeric': 0.013215859030837005, 'fraction_numerical': 0.003303964757709251, 'mean_word_length': 5.446808510638298, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Neuroprogression in schizophrenia: Pathways and underpinning clinical staging and therapeutic corollaries

Australian & New Zealand Journal of Psychiatry, 49(2) clinicians and patients. If rTMS is to become part of our therapeutic repertoire, then as a profession we will need to find effective ways to achieve acceptance by both Medicare and the private health funds. This requires active engagement by the Royal Australian and New Zealand College of Psychiatrists in the task of promoting rTMS as a safe and effective treatment, and investment by the profession in developing the resources and expertise required to participate in the bureaucratic processes required for funding approval. Given the growing pipeline of new brain stimulation treatments, this investment should not be seen to be short term and solely focussed on rTMS but a critical part of expanding the psychiatric treatment armamentarium.